Iradokizunak:
evolves. » evolved. (Hedatu), evolve. (Hedatu)
revolves. » revolved. (Hedatu), revolve. (Hedatu), resolves. (Hedatu), evolved. (Hedatu), evolve. (Hedatu)
evolves. » evolved. (Hedatu), evolve. (Hedatu)
revolves. » revolved. (Hedatu), revolve. (Hedatu), resolves. (Hedatu), evolved. (Hedatu), evolve. (Hedatu)
-
3301
Image_1.PDF
Argitaratua 2018“...<p>The freshwater cyanobacterium Microcystis aeruginosa frequently forms toxic massive blooms and exists in an arms race with its infectious phages in aquatic natural environments, and as a result, has evolved extremely diverse and elaborate antiviral defense systems, including the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated genes (Cas) system. ...”
-
3302
Data Sheet 1_Quantification of bactericidal activity using the PATHFAST TB LAM Ag assay during the first 14 days of pulmonary tuberculosis treatment.docx
Argitaratua 2025“...</p>Methods<p>We conducted a retrospective longitudinal repository study using stored sputum samples from 14-day early bactericidal activity trials involving 75 pulmonary TB patients who received one of five different regimens. ...”
-
3303
Victim demographics and DWI outcomes from perpetrators using particular methods: analysis of 60,481 Iraqi civilian deaths from short-duration violence, March 20, 2003 through March...
Argitaratua 2013“...</p>c<p>Unless noted, data are for events involving the single method used alone (e.g., small arms gunfire only, not combined gunfire and mortar fire)....”
-
3304
Image3_Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice.tiff
Argitaratua 2022“...<p>Many inborn errors of metabolism require life-long treatments and, in severe conditions involving the liver, organ transplantation remains the only curative treatment. ...”
-
3305
Image5_Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice.tiff
Argitaratua 2022“...<p>Many inborn errors of metabolism require life-long treatments and, in severe conditions involving the liver, organ transplantation remains the only curative treatment. ...”
-
3306
Image1_Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice.tiff
Argitaratua 2022“...<p>Many inborn errors of metabolism require life-long treatments and, in severe conditions involving the liver, organ transplantation remains the only curative treatment. ...”
-
3307
Image4_Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice.tiff
Argitaratua 2022“...<p>Many inborn errors of metabolism require life-long treatments and, in severe conditions involving the liver, organ transplantation remains the only curative treatment. ...”
-
3308
Image2_Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice.tiff
Argitaratua 2022“...<p>Many inborn errors of metabolism require life-long treatments and, in severe conditions involving the liver, organ transplantation remains the only curative treatment. ...”
-
3309
Table1_Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice.pdf
Argitaratua 2022“...<p>Many inborn errors of metabolism require life-long treatments and, in severe conditions involving the liver, organ transplantation remains the only curative treatment. ...”
-
3310
DataSheet_1_PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer.docx
Argitaratua 2023“...The dual function of PTCH1 as a multidrug efflux pump and a hedgehog receptor, and the active involvement of CTNNB1 in breast cancer strongly indicate that PTCH1 and CTNNB1 can be potential drug targets to overcome chemoresistance in ER +/HER2- breast cancer patients....”
-
3311
(A) Creation of a genetic rescue construct encoding fused with an N-terminal FLAG-tetracysteine tag (4C),
Argitaratua 2011“...(b) PCR product containing left (L) and right (R) homology arms, the 4C tag, and LoxP site (gray triangles) flanked marker. ...”
-
3312
Background Selection as Baseline for Nucleotide Variation across the <i>Drosophila</i> Genome
Argitaratua 2014“...<div><p>The constant removal of deleterious mutations by natural selection causes a reduction in neutral diversity and efficacy of selection at genetically linked sites (a process called Background Selection, BGS). ...”
-
3313
Table_1_Source localized infraslow neurofeedback training in people with chronic painful knee osteoarthritis: A randomized, double-blind, sham-controlled feasibility clinical trial...
Argitaratua 2022“...Eligible participants attended nine 30-min ISF-NF training sessions involving three cortical regions linked to pain. Feasibility measures were monitored during the trial period. ...”
-
3314
DataSheet_2_Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.csv
Argitaratua 2023“...Introduction<p>Drug resistance is a major obstacle in cancer treatment and can involve a variety of different factors. Identifying effective therapies for drug resistant tumors is integral for improving patient outcomes....”
-
3315
Timing of Antibiotic Prophylaxis in Elective Caesarean Delivery: A Multi-Center Randomized Controlled Trial and Meta-Analysis
Argitaratua 2015“...</p><p>Methods</p><p>We conducted a randomized open-label controlled trial with two parallel arms at three hospitals in western China. Participants meeting the inclusion criteria received antibiotics 30-60 minutes before skin incision while others received antibiotics after umbilical cords clamping. ...”
-
3316
Table1_Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis.docx
Argitaratua 2023“...</p><p>Results: There were five studies involving 492 patients included in the study. Combination therapy did not significantly improve clinical outcomes in terms of 1-year OS [RR = 1.02, 95%CI = (0.82–1.25)], 2-year OS [RR = 1.00, 95%CI = (0.67–1.49)], 4-month PFS [RR = 1.00, 95%CI = (0.67–1.49)], 1-year PFS [RR = 0.79, 95%CI = (0.44–1.42)], and ORR [OR = 0.79, 95%CI = (0.49–1.27)] compared to chemotherapy alone, and the subgroup analysis of 2-year OS, 1-year PFS, and ORR based on countries and tumor sites showed similar results. ...”
-
3317
Early Sitting in Ischemic Stroke Patients (SEVEL): A Randomized Controlled Trial
Argitaratua 2016“...Taking these limitations into account, our results may help guide the development of more effective acute stroke rehabilitation strategies, and the design of future acute stroke trials involving out of bed activities and other mobilization regimens....”
-
3318
DataSheet_1_Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.csv
Argitaratua 2023“...Introduction<p>Drug resistance is a major obstacle in cancer treatment and can involve a variety of different factors. Identifying effective therapies for drug resistant tumors is integral for improving patient outcomes....”
-
3319
DataSheet_1_Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.docx
Argitaratua 2023“...Introduction<p>Drug resistance is a major obstacle in cancer treatment and can involve a variety of different factors. Identifying effective therapies for drug resistant tumors is integral for improving patient outcomes....”
-
3320
Conditional Chr 13 <i>PRELI</i> gene Targeting.
Argitaratua 2013“...Also indicated are 5′ and 3′ arms of homology, LoxP sites, Flip recombination (Frt) sequences, and PGK-Neo and HSV-Tk selection cassettes; <b>III</b>: Floxed <i>PRELI</i> allele, after Frt-mediated removal of selection cassettes; <b>IV</b>: <i>PRELI</i> deficient allele after CD19-driven Cre recombinase (Cre) cleavage of <i>PRELI</i> exon II. ...”